The company made this announcement after trading hours on Thursday, 27 March 2008.
Meanwhile, the BSE Sensex was down 78.14 points, or 0.49%, to 15,937.42.
On BSE, 55,416 shares were traded in the counter. The scrip had an average daily volume of 1.42 lakh shares in the past one quarter.
The stock hit a high of Rs 145 and a low of Rs 138.25 so far during the day. The stock had a 52-week high of Rs 242.35 on 30 July 2007 and a 52-week low of Rs 109.05 on 24 March 2008.
The small-cap scrip had underperformed the market over the past one month till 27 March 2008, declining 15.60% compared to the Sensex’s fall of 10.16%. It had also underperformed the market in the past one quarter, declining 27.03% compared to Sensex’s decline of 20.74%.
The company’s current equity is Rs 18.13 crore. Face value per share is Rs 10.
The current price of Rs 143.05 discounts its Q3 December 2007 annualized EPS of Rs 17.39, by a PE multiple of 8.23.
The company has also concluded a long-term business contract with Merck Life Sciences.
Jupiter Bioscience’s net profit rose 9.3% to Rs 7.88 crore on 13.7% growth in net sales to Rs 31.42 crore in Q3 December 2007 over Q3 December 2006.
The company is engaged in manufacturing peptide group products, drug intermediates, and fine chemicals. The group has developed three types of molecules to treat human and animal disease small molecules, antibodies and peptides.
Meanwhile, the BSE Sensex was down 78.14 points, or 0.49%, to 15,937.42.
On BSE, 55,416 shares were traded in the counter. The scrip had an average daily volume of 1.42 lakh shares in the past one quarter.
The stock hit a high of Rs 145 and a low of Rs 138.25 so far during the day. The stock had a 52-week high of Rs 242.35 on 30 July 2007 and a 52-week low of Rs 109.05 on 24 March 2008.
The small-cap scrip had underperformed the market over the past one month till 27 March 2008, declining 15.60% compared to the Sensex’s fall of 10.16%. It had also underperformed the market in the past one quarter, declining 27.03% compared to Sensex’s decline of 20.74%.
The company’s current equity is Rs 18.13 crore. Face value per share is Rs 10.
The current price of Rs 143.05 discounts its Q3 December 2007 annualized EPS of Rs 17.39, by a PE multiple of 8.23.
The company has also concluded a long-term business contract with Merck Life Sciences.
Jupiter Bioscience’s net profit rose 9.3% to Rs 7.88 crore on 13.7% growth in net sales to Rs 31.42 crore in Q3 December 2007 over Q3 December 2006.
The company is engaged in manufacturing peptide group products, drug intermediates, and fine chemicals. The group has developed three types of molecules to treat human and animal disease small molecules, antibodies and peptides.
No comments:
Post a Comment